西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症疗效和安全性的回顾性研究

薛梅萍; 郑茹萍; 林惠娥; 甘惠贞

doi:10.3969/j.issn.1006-0111.2018.05.020

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症疗效和安全性的回顾性研究

薛梅萍, 郑茹萍, 林惠娥, 甘惠贞

文章导航 > 药学实践与服务 > 2018 > 36(5): 468-470

薛梅萍, 郑茹萍, 林惠娥, 甘惠贞. 西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症疗效和安全性的回顾性研究[J]. 药学实践与服务, 2018, 36(5): 468-470. doi: 10.3969/j.issn.1006-0111.2018.05.020

引用本文:

XUE Meiping, ZHENG Ruping, LIN Huie, GAN Huizhen. Retrospective study on efficacy and safety of combination therapy of sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(5): 468-470. doi: 10.3969/j.issn.1006-0111.2018.05.020

Citation:

XUE Meiping, ZHENG Ruping, LIN Huie, GAN Huizhen. Retrospective study on efficacy and safety of combination therapy of sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(5): 468-470. doi: 10.3969/j.issn.1006-0111.2018.05.020

西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症疗效和安全性的回顾性研究

doi: 10.3969/j.issn.1006-0111.2018.05.020

解放军180医院药学科, 福建泉州 362000

Retrospective study on efficacy and safety of combination therapy of sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia

Department of Pharmacy, No. 180 Hospital of PLA, Quanzhou 362000, China

摘要: 目的探讨西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症的疗效和安全性。方法采用回顾性分析法，收集解放军180医院内分泌科门诊脆性糖尿病伴高脂血症患者158例，其中，单用预混胰岛素治疗的78例为对照组，西格列汀联合预混胰岛素治疗的80例为治疗组，随访时间为36周。比较两组治疗前后糖化血红蛋白（HbAlc）、空腹血糖（FPG）、餐后血糖（PPG）、空腹C肽、餐后2 h C肽，每日血糖谷峰浓度均差（△TP）、血脂水平变化及低血糖发生率。结果治疗后联合组FPG、PPG、△TP、总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白（LDL-C）较治疗前均有明显下降（P<0.05，P<0.01），且均低于对照组（P<0.05，P<0.01）；联合组空腹C肽和餐后2 h C肽较治疗前显著升高（P<0.01），且均高于对照组（P<0.05）。结论西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症可显著改善患者血糖和血脂水平，且不良反应更少。
- 脆性糖尿病 /
- 西格列汀 /
- 预混胰岛素 /
- 疗效 /
- 安全性
Abstract: Objective To investigate the efficacy and safety of combination therapy with sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia. Methods 158 patients treated at endocrinology clinic in our hospital for brittle diabetes with hyperlipidemia were selected for the retrospective analysis. 78 patients received insulin alone were severed as the control group while 80 patients treated with sitagliptin and premixed insulin as the treatment group. The follow-up time was 36 weeks. The levels of HbAlc, FPG, PPG, fasting C peptide, postprandial 2 h C peptide, average difference of daily trough and peak blood glucose level (△TP), blood lipid level and hypoglycemia incidences were compared before and after treatment between two groups. Results After treatment,the levels of FPG, PPG, △TP, TC, TG and LDL-C in the combination therapy group were significantly lower than the level before treatment (P<0.05,P<0.01). Those values in the treated group were also lower than the control group (P<0.05,P<0.01). The fasting C peptide and postprandial 2 h C peptide in the combination therapy group were significantly higher than level before treatment (P<0.01).Those values were higher in the treated group compared to the control group (P<0.05). Conclusion Combination therapy of sitagliptin and premixed insulin for the treatment of brittle diabetes with hyperlipidemia can significantly improve patients' blood glucose and lipid levels with less adverse reactions.
- brittle diabetes /
- sitagliptin /
- premixed insulin /
- efficacy /
- safety

[1]	VANTYGHEM MC,PRESS M. Management strategies for brittle diabetes[J]. Ann Endocrinol(Paris),2006,67(4):287-296.
[2]	AMETOV AS,KULIDZHANIAN NK. Diabetes mellitus is an independent risk factor for cardiovascular disease[J]. Ter Arkh,2012,84:91-94.
[3]	KIM D,WANG L,BECONI M,et al. (2R)-4-oxo-4-triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine:a potent,orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes[J]. J Med Chem,2005,48(6):141-151.
[4]	DRUKER DJ, NAUCK MA. GLP-1R agonists(incretin mimetics) and DPP-4 inhibitors (incretin enhancers) for the treatment of type 2 diabetes[J]. Lancet, 2006, 368(3):1696-1705.
[5]	DRUCKER DJ. Enhancing incretin action for the treatment of type 2 diabetes[J]. Diabetes Care,2003,26(10):2929-2940.
[6]	LIU XM. Special complication of diabetes[M]//LIU Xinmin. Practical endocrinology. 2nd ed. Beijing:People's Military Medical Publishing House, 1997:356-358.
[7]	郭慧,刘良专,刘江华. 降脂通络软胶囊联合瑞舒伐他汀对2型糖尿病合并高血脂症患者效果观察[J]. 重庆医学,2015,44(24):3348-3349.
[8]	HOLST JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide 1[J]. Diabetes Metab Res Rev,2002,18(6):430-441.
[9]	徐晓菲,吴玉波,吴禹蒙. 西格列汀对2型糖尿病患者血脂水平影响的系统评价[J]. 中国药房,2015,26(6):784-787.
[10]	罗娜,朱妍,张真稳,等. 西格列汀联合胰岛素治疗脆性糖尿病的临床观察[J]. 中南大学学报(医学版),2015,40(10):1089-1095.

[1]	杨嘉宁, 赵一颖, 肖伟. 七味脂肝方对非酒精性脂肪性肝炎动物模型的药效学评价 . 药学实践与服务, 2024, 42(9): 389-398. doi: 10.12206/j.issn.2097-2024.202404096
[2]	迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛. 负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
[3]	戴菲菲, 傅翔, 陈琼年, 俞苏纯. 上海某二级医院革兰阴性菌流行特征的回顾性分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202305005
[4]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[5]	桂明珠, 李静, 李志玲. 儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
[6]	孙丹倪, 黄勇, 张嘉宝, 王培. 代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
[7]	王耀振, 徐灿, 吕顺莉, 田泾, 张东炜. 钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
[8]	张晶晶, 索丽娜, 郑兆红. 89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
[9]	陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾. 基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 479-486. doi: 10.12206/j.issn.2097-2024.202401073
[10]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[11]	李想, 陆鸿远, 张明玉, 高欢, 姚东, 许子华. 米格列醇激活UCP1介导棕色脂肪对冷暴露小鼠损伤的研究 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202404005
[12]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202401050
[13]	毛智毅, 王筱燕, 陈晓颖, 汤逸斐. 度拉糖肽联合二甲双胍对肥胖型2型糖尿病患者机体代谢、体脂成分及血清脂肪因子的影响 . 药学实践与服务, 2024, 42(7): 305-309. doi: 10.12206/j.issn.2097-2024.202305032
[14]	徐璐璐, 刘爱军. 丹参白术方“异病同治”冠心病、血管性痴呆、特发性膜性肾病的网络药理学作用机制研究 . 药学实践与服务, 2024, 42(12): 1-8. doi: 10.12206/j.issn.2097-2024.202312027
[15]	刘依秦, 王超群, 邱娇娜. 胆宁片预处理在糖尿病患者结肠镜检查前的应用效果分析 . 药学实践与服务, 2024, 42(9): 407-410. doi: 10.12206/j.issn.2097-2024.202407037
[16]	陈春娟, 郑志新, 李骊. 平喘方联合孟鲁司特钠治疗儿童支气管哮喘患者的临床疗效观察 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202405035
[17]	徐飞, 陈瑾, 鲁育含, 李志勇. 肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023
[18]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044

点击查看大图

计量

文章访问数: 3105
HTML全文浏览量: 353
PDF下载量: 360
被引次数: 0

西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症疗效和安全性的回顾性研究

doi: 10.3969/j.issn.1006-0111.2018.05.020

解放军180医院药学科, 福建泉州 362000

收稿日期: 2017-12-19
修回日期: 2018-03-05

关键词:

疗效 /

摘要: 目的探讨西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症的疗效和安全性。方法采用回顾性分析法，收集解放军180医院内分泌科门诊脆性糖尿病伴高脂血症患者158例，其中，单用预混胰岛素治疗的78例为对照组，西格列汀联合预混胰岛素治疗的80例为治疗组，随访时间为36周。比较两组治疗前后糖化血红蛋白（HbAlc）、空腹血糖（FPG）、餐后血糖（PPG）、空腹C肽、餐后2 h C肽，每日血糖谷峰浓度均差（△TP）、血脂水平变化及低血糖发生率。结果治疗后联合组FPG、PPG、△TP、总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白（LDL-C）较治疗前均有明显下降（P<0.05，P<0.01），且均低于对照组（P<0.05，P<0.01）；联合组空腹C肽和餐后2 h C肽较治疗前显著升高（P<0.01），且均高于对照组（P<0.05）。结论西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症可显著改善患者血糖和血脂水平，且不良反应更少。

English Abstract

Retrospective study on efficacy and safety of combination therapy of sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia

Department of Pharmacy, No. 180 Hospital of PLA, Quanzhou 362000, China

Received Date: 2017-12-19
Rev Recd Date: 2018-03-05

Keywords:

Abstract: Objective To investigate the efficacy and safety of combination therapy with sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia. Methods 158 patients treated at endocrinology clinic in our hospital for brittle diabetes with hyperlipidemia were selected for the retrospective analysis. 78 patients received insulin alone were severed as the control group while 80 patients treated with sitagliptin and premixed insulin as the treatment group. The follow-up time was 36 weeks. The levels of HbAlc, FPG, PPG, fasting C peptide, postprandial 2 h C peptide, average difference of daily trough and peak blood glucose level (△TP), blood lipid level and hypoglycemia incidences were compared before and after treatment between two groups. Results After treatment,the levels of FPG, PPG, △TP, TC, TG and LDL-C in the combination therapy group were significantly lower than the level before treatment (P<0.05,P<0.01). Those values in the treated group were also lower than the control group (P<0.05,P<0.01). The fasting C peptide and postprandial 2 h C peptide in the combination therapy group were significantly higher than level before treatment (P<0.01).Those values were higher in the treated group compared to the control group (P<0.05). Conclusion Combination therapy of sitagliptin and premixed insulin for the treatment of brittle diabetes with hyperlipidemia can significantly improve patients' blood glucose and lipid levels with less adverse reactions.

引用本文:

Citation:

XUE Meiping, ZHENG Ruping, LIN Huie, GAN Huizhen. Retrospective study on efficacy and safety of combination therapy of sitagliptin and premixed insulin in the treatment of brittle diabetes with hyperlipidemia[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(5): 468-470. doi: 10.3969/j.issn.1006-0111.2018.05.020